| 1.205 0.105 (9.55%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.66 |
1-year : | 2.02 |
| Resists | First : | 1.42 |
Second : | 1.73 |
| Pivot price | 1.15  |
|||
| Supports | First : | 0.93 |
Second : | 0.77 |
| MAs | MA(5) : | 1.13 |
MA(20) : | 1.21 |
| MA(100) : | 1.13 |
MA(250) : | 2.1 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 28.3 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 4.4 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AKTX ] has closed below upper band by 27.8%. Bollinger Bands are 63% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.29 | 1.29 - 1.29 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Thu, 17 Apr 2025
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Wed, 16 Apr 2025
Akari Therapeutics PLC Reports $21.6 Million Net Loss for 2024 Amid Strategic ADC Development Focus - GuruFocus
Wed, 16 Apr 2025
Akari Therapeutics Cash On Hand Expected To Be Sufficient To Fund Planned Operations Into September 2025 - marketscreener.com
Wed, 16 Apr 2025
Akari Therapeutics (AKTX) Poised for Growth After Completing Merger with Peak Bio | AKTX Stock News - GuruFocus
Wed, 16 Apr 2025
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Wed, 16 Apr 2025
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 19,790 (M) |
| Held by Insiders | 44.7 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 86 (K) |
| Shares Short P.Month | 78 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.47 |
| PEG Ratio | 0 |
| Price to Book value | -2.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|